4.5 Review

Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies

Journal

CANCER AND METASTASIS REVIEWS
Volume 40, Issue 1, Pages 319-339

Publisher

SPRINGER
DOI: 10.1007/s10555-020-09937-z

Keywords

Centrosome amplification; Prognostic biomarker; Solid tumors; Formalin-fixed paraffin-embedded tissue sections; DCIS

Categories

Funding

  1. National Cancer Institute [U01 CA179671]

Ask authors/readers for more resources

This article discusses the prevalence of centrosome amplification (CA) in various solid cancers, as well as the utility of quantifying amplified centrosomes as an independent prognostic marker. It also reviews the progression of CA in breast cancer and the potential role of CA in promoting tumor progression and metastasis.
Numerical and/or structural centrosome amplification (CA) is a hallmark of cancers that is often associated with the aberrant tumor karyotypes and poor clinical outcomes. Mechanistically, CA compromises mitotic fidelity and leads to chromosome instability (CIN), which underlies tumor initiation and progression. Recent technological advances in microscopy and image analysis platforms have enabled better-than-ever detection and quantification of centrosomal aberrancies in cancer. Numerous studies have thenceforth correlated the presence and the degree of CA with indicators of poor prognosis such as higher tumor grade and ability to recur and metastasize. We have pioneered a novel semi-automated pipeline that integrates immunofluorescence confocal microscopy with digital image analysis to yield a quantitative centrosome amplification score (CAS), which is a summation of the severity and frequency of structural and numerical centrosome aberrations in tumor samples. Recent studies in breast cancer show that CA increases across the disease progression continuum, while normal breast tissue exhibited the lowest CA, followed by cancer-adjacent apparently normal, ductal carcinoma in situ and invasive tumors, which showed the highest CA. This finding strengthens the notion that CA could be evolutionarily favored and can promote tumor progression and metastasis. In this review, we discuss the prevalence, extent, and severity of CA in various solid cancer types, the utility of quantifying amplified centrosomes as an independent prognostic marker. We also highlight the clinical feasibility of a CA-based risk score for predicting recurrence, metastasis, and overall prognosis in patients with solid cancers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available